# A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

> **NCT04552899** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 665 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** PRM-151 (Zinpentraxin Alfa)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04552899
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-19
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 665 (ACTUAL)
- **Why stopped:** The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552899, "A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04552899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*